EZH2 and breast carcinoma: In particular, the methyltransferase EZH2/KMT6A and its end-product H3K27me3 mark are found elevated in aggressive breast cancer subtypes, including triple negative and ERα-positive tumors resistant to endocrine therapies, suggesting inactivation of tumor suppressor genes [31, 35–38].